ENDOXAN
 |
|
|
Package(a):
VIALS (powder for reconstitution): 10 x 10 ml (200 mg).
Dosage(a):
See prescribing information for full details.
Prescribing Restrictions: None
Package(b):
VIALS (powder for reconstitution): 50 x 10 ml (200 mg).
Dosage(b):
See prescribing information for full details.
Prescribing Restrictions: None
Package(c):
VIALS (powder for reconstitution): 1 x 25 ml (500 mg).
Dosage(c):
See prescribing information for full details.
Prescribing Restrictions: None
Package(d):
VIALS (powder for reconstitution): 1 x 50 ml (1G).
Dosage(d):
See prescribing information for full details.
Prescribing Restrictions: None
Indications:
Malignant lymphoma, Hodgkin’s disease, lymphocytic lymphoma, mixed cell type lymphoma, Burkitt’s lymphoma, multiple myeloma, leukememia, mycosis fungoides, neuroblastoma, ovary adenocarcinoma, retinoblastoma, breast carcinoma, SLE.
Contra-Indications:
Hypersensitivity, patients with severely depressed bone marrow function, pregnancy, lactation.
Special Precautions:
Use in pregnancy and lactation, patients with leukopenia, thrombocytopenia, tumor cell infiltration of bone marrow, previous radiation therapy, previous cytotoxic therapy, impaired hepatic function, impaired renal function, interruption or modification of dosage should be considered for patients who develop bacterial, fungal or viral infections. This is especially true for patients receiving concomitant steroid therapy or who have recently received steroid therapy, since such infections may be fatal. May suppress positive reactions to the following skin tests: Candida, mumps, Trichophyton and tuberculin purified protein derivative (PPD). Serum pseudocholinesterase may be decreased. Blood and urine uric acid levels may be increased. May produce a false-positive Papanicolaou test.
Side Effects:
Secondary neoplasia has developed with cyclophosphamide alone or with other antineoplastic drugs or radiation therapy. Leukopenia is an expected effect and is used as a guide to dosage. Thrombocytopenia or anemia occur rarely. Anorexia, nausea, vomiting, diarrhea and stomatitis are common. Urinary tract complications occur in about 25% of cases and acute hemorrhagic cystitis occurs in 7-12%. (SIADH) has been reported with i.v. doses greater than 50 mg/kg body weight. Alopecia, interstitial pulmonary fibrosis, cardiotoxicity, hypersensitivity reactions (type 1).
Drug Interactions:
Allopurinol, ACE inhibitors, doxorubicin, oral hypoglycemics, liver enzyme inducers e.g. rifampicin.
